Failed Trials News Today

Experts discuss the profound impact of seborrheic dermatitis on a patients' well-being, examining the common misconceptions, diagnostic delays, and societal judgments that hinder effective management and necessitate enhanced clinical outreach and patient education.

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

Oxurion is left with one last shot at success.

AbbVie is cutting a cystic fibrosis medicine after an interim analysis revealed that the therapy did nothing when added to a triple-combo regimen.

Bristol Myers Squibb and Nektar have read the last rites to their huge, failed cancer collaboration.

Roche’s gamble on anti-TIGIT drug tiragolumab in small cell lung cancer (SCLC) has flamed out.

Early underwhelming data from Icosavax's COVID-19 vaccine has sent investors sprinting towards the exits, bringing into question whether the biotech's entire platform has a "fatal flaw." 

BridgeBio's shot at entering a competitive market for a rare heart condition narrowed Monday after a "baffling" result in a phase 3 clinical trial where placebo patients bested those who received the treatment in a walk test. 

Dicerna is still paving a way forward for its troubled late-stage RNAi asset nedosiran as it looks to gun for an FDA approval in just one sub-type of a rare disease after ratcheting up another mixed bag of data.

Atea Pharmaceuticals and Roche have suffered a big blow to their bid to bring an oral antiviral for COVID-19 to market. A phase 2 trial of the candidate missed its primary endpoint, prompting Atea and Roche to consider changes that will delay data from a pivotal study by around one year.